Skip to content
DataLookout
Menu

NCT07503444

A Phase 3 Study of Fenfluramine Hydrochloride in Rett Syndrome

StatusRecruiting
PhasePhase 3
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 13 versions: 13 with changes below. See every version on ClinicalTrials.gov ↗

  1. Minor Trial sites expanded: 40 → 46 locations
  2. Minor Trial sites expanded: 32 → 40 locations
  3. Minor Study sites: 32 to 33
  4. Minor Trial sites expanded: 23 → 32 locations
  5. Notable Eligibility criteria expanded, about 22 words
    • Trial sites expanded: 18 → 23 locations
    • Secondary endpoints: details revised at 17 of 17 entries
  6. Notable Primary completion pushed from Aug 1, 2028 to Feb 6, 2029v8 Show 6 more changesShow less
    • Recruitment opened
    • Eligibility criteria expanded, about 2 words
    • Trial sites expanded: 10 → 18 locations
    • Study completion pushed from Nov 15, 2030 to Aug 29, 2031
    • Start date changed from estimate of Jun 30, 2026 to Jul 14, 2026
    • Secondary endpoints: 10 to 17
  7. Minor Study sites: 9 to 10v7
  8. Minor Trial sites expanded: 5 → 9 locationsv6
  9. Notable Start date: May 31, 2026 to Jun 30, 2026v5
  10. Minor Study sites: 4 to 5v4
  11. Minor Study sites: 2 to 4v3
  12. Notable Start date: Mar 31, 2026 to May 31, 2026
    • Study sites: 0 to 2
    • Secondary endpoints revised (10)
    v2
  13. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Change from Baseline to Week 14 in Rett Syndrome Behaviour Questionnaire (RSBQ) Total Score
Timeframe: From Baseline (Day 1) to Week 14
Clinical Global Impression of Change (CGIC) Score at Week 14
Timeframe: At Week 14

Secondary (17)

Change from Baseline to Week 14 in Patient-Reported Outcomes Measurement Information System-Sleep Disturbance (PROMIS-SD) score
Change from Baseline to Week 14 in Observer-Reported Communication Ability (ORCA) score
Caregiver Global Impression of Change - Seizure (CaGIC-Seizure) score at Week 14
Incidence of treatment-emergent adverse events (TEAEs) during the double-blind intervention period
Incidence of serious TEAEs during the double-blind intervention period
Show 12 moreShow less
Incidence of TEAEs leading to discontinuation during the double-blind intervention period
Incidence of related TEAEs during the double-blind intervention period
Change from Baseline in QT interval corrected using Fridericia's formula (QTcF) interval on 12-lead ECG by visit during the double-blind intervention period
Incidence of treatment-emergent Doppler Echocardiogram (ECHO) results meeting the Food and Drug Administration (FDA) case definition of drug-associated valvular heart disease (VHD) during the double-blind intervention period
Incidence of treatment-emergent Doppler ECHO results meeting the FDA case definition of PAH (defined as a PASP >35mmHg) during the double-blind intervention period
Incidence of treatment-emergent adverse events (TEAEs) from baseline to end of safety follow up
Incidence of serious TEAEs from baseline to end of safety follow up
Incidence of TEAEs leading to discontinuation from baseline to end of safety follow up
Incidence of related TEAEs from baseline to end of safety follow up
Change from Baseline in QT interval corrected using Fridericia's formula (QTcF) interval on 12-lead ECG by visit from baseline to end of safety follow up
Incidence of treatment-emergent Doppler Echocardiogram (ECHO) results meeting the Food and Drug Administration (FDA) case definition of drug-associated valvular heart disease (VHD) from baseline to end of safety follow up
Incidence of treatment-emergent Doppler ECHO results meeting the FDA case definition of PAH (defined as a PASP >35mmHg) from baseline to end of safety follow up

Arms and interventions

fenfluramine hydrochlorideExperimental

Participants will receive fenfluramine hydrochloride for 14 weeks in a double-blind period (including titration and maintenance), followed by a 2-week double-blind transition period. This is followed by a 52-week open-label treatment period. Participants may continue treatment until alternative access is available. Those who discontinue without continued access will undergo an 8-day taper and a 26-week follow-up.

PlaceboPlacebo comparator

Participants will receive a matching placebo for 14 weeks in a double-blind period (including titration and maintenance). After this period, they transition into a 2-week double-blind period with fenfluramine hydrochloride, followed by a 52-week open-label treatment period. Participants may continue treatment until alternative access is available. Those who discontinue without continued access will undergo an 8-day taper and a 26-week follow-up.

Drugs: fenfluramine hydrochloride

Other: Placebo

Sites

46 sites in 13 countries

United States 8, Italy 7, Japan 6, France 5, Spain 5, United Kingdom 3, Belgium 2, China 2, Georgia 2, Hungary 2, Poland 2, Germany 1, Israel 1